The antiarrhythmic and antifibrillatory effects of flecainide acetate during the early postinfarction period were evaluated in a conscious canine model of sudden cardiac death. Ventricular tachycardia remained inducible early after infarction in eight of nine dogs receiving an intravenous loading dose offtecainide (2.0 mg/kg body weight) and seven of eight dogs receiving saline vehicle. In both the drug and vehicle groups, there was no significant change in the ventricular refractory period or in the cycle length of the induced ventricular tachycardia. With a maintenance intravenous infusion of flecainide, 1.0 mg/kg per h for 4 hours, the subsequent occurrence of acute posterolateral ischemia resulted in the development of ventricular fibrillation and sudden death in seven of eight flecainide-treated and eight of eight vehicle-treated dogs.
The antiarrhythmic and antifibrillatory effects of flecainide acetate during the early postinfarction period were evaluated in a conscious canine model of sudden cardiac death. Ventricular tachycardia remained inducible early after infarction in eight of nine dogs receiving an intravenous loading dose offtecainide (2.0 mg/kg body weight) and seven of eight dogs receiving saline vehicle. In both the drug and vehicle groups, there was no significant change in the ventricular refractory period or in the cycle length of the induced ventricular tachycardia. With a maintenance intravenous infusion of flecainide, 1.0 mg/kg per h for 4 hours, the subsequent occurrence of acute posterolateral ischemia resulted in the development of ventricular fibrillation and sudden death in seven of eight flecainide-treated and eight of eight vehicle-treated dogs.
In the continuing search for antiarrhythmic agents with greater therapeutic efficacy and less toxicity. ftecainide acetate appears to be one of the most promising recently introduced drugs (1-5). Previous clinical studies in the United States and Europe (6) (7) (8) (9) have demonstrated encouraging efficacy in the reduction of the frequency of chronic, stable ventricular ectopic complexes. In patients with documented ventricular tachyarrhythmias, Reid et al. (10) reported an 89% rate of efficacy for the prevention of ventricular tachycardia during Holter electrocardiographic monitoring, whereas Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given ftecainide in an intravenous loading and maintenance dosing regimen. The subsequent occurrence of posterolateral ischemia resulted in the development of ventricular fibrillation in three of these seven dogs.
These findings suggest that ftecainide acetate may not possess pharmacologic properties useful in managing ventricular tachycardia or in preventing ischemic ventricular fibrillation in the presence of recent myocardial damage. Anderson et al. (I I , 12) reported a 60% success rate in the suppression of ventricular tachycardia induction by programmed pacing techniques with flecainide. However, the efficacy of flecainide in the prevention of ventricular tachyarrhythmias or sudden death, or both, in patients in the early stages after myocardial infarction has not been evaluated extensively. In the present study, we examined the efficacy of ftecainide acetate on the electrical induction of ventricular tachycardia and the occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period in a conscious canine model of sudden death (13, 14) . The essential experimental features of this model are illustrated in Figure I .
Methods
Surgical preparation. The surgical preparation of dogs for later electrophysiologic studies has been described previously in detail (\5,16). Briefly, anterior myocardial in- Figure 1 . Consciouscanine modelof suddendeath. Anteriormyocardial ischemic injury (broken lines) is produced by a 2 hour occlusion of the left anterior descendingcoronary artery, followed by reperfusion through a critical stenosis. An epicardial bipolar electrode (A) is suturedto the left atrial appendagefor atrial pacing. A bipolar plunge electrode (B) is inserted into the interventricular septum, adjacent to the site of coronary artery occlusion, for the determination of ventricularexcitation threshold, effective refractory period and for the delivery of programmed ventricular extrastimuli. The bared tip of an insulated silver wire (C) is inserted into the lumen of the proximal left circumflex coronary artery, and the wire is sutured onto the surface of the heart. Dogs are returned to the laboratory for electrophysiologic study 4 to 7 days after surgical preparation.
farction was produced by a 2 hour occlusion of the mid-left anterior descending coronary artery, followed by reperfusion in the presence of a critical stenosis at the site of the previous occlusion. Instrumentation for subsequent studies included indwelling arterial and venous cannulas, bipolar plunge electrodes sutured to the left atrial appendage and right ventricular outflow tract and a 30 gauge silver wire electrode inserted into the lumen of the left circumflex coronary artery (3 mm in contact with the endothelium), I cm from its origin (Fig. I) .
Programmed ventricular stimulation and electrophysiologic testing. Electrophysiologic studies were performed in 26 conscious, unsedated animals 4 to 7 (mean ± 5 SEM 6 ± I) days after infarction. Electrocardiographic intervals and electrophysiologic variables were determined immediately before ventricular stimulation. Programmed stimulation was performed using I to 3 extrastimuli during sinus rhythm and during atrial pacing (2.5 Hz), by methods described previously (15, 16) . During the introduction of single extrastimuli (S2), the basic S I S2 coupling interval ranged from 350 ms to the point of ventricular refractoriness. With double and triple extrastimuli, S2S3 and S2S3S4 intervals ranged from 182 to 125 ms. The end point of stimulation was the reproducible induction of ventricular tachycardia or completion of the protocol.
Nonsustained ventricular tachycardia was defined as five or more repetitive complexes that terminated spontaneously within 30 seconds. Sustained ventricular tachycardia persisted at least 30 seconds or, in the event of hemodynamic compromise, required pacing techniques for termination. If nonsustained ventricular tachycardia could be initiated reproducibly, more aggressive attempts to induce sustained tachycardia were not made. If induced ventricular tachycardia at baseline degenerated rapidly to ventricular fibrillation, the animal was not resuscitated, to avoid the confounding influence of repeated and occasionally prolonged resuscitative efforts on the outcome of subsequent investigations. Two animals were excluded from the study because they responded to pretreatment programmed stimulation with ventricular fibrillation.
Ventricular excitation threshold and effective refractory period were measured during atrial pacing (2.5 Hz). The ventricular excitation threshold was defined as the minimal voltage required to capture the ventricle with a single extrastimulus of 4 ms duration delivered 300 ms after the R wave of the lead II electrocardiogram. The ventricular effective refractory period was defined as the longest R to stimulus interval at which a 2 x threshold stimulus (4 ms duration) failed to capture the ventricle.
Conscious canine model of sudden coronary death: ventricular fibrillation in response to ischemia at a site distant from a previous myocardial infarction. After the completion of posttreatment programmed ventricular stimulation, an anodal current of 150 /LA was applied to the intimal surface of the left circumflex coronary artery of drugand vehicle-treated postinfarction dogs by way of the intracoronary silver wire electrode. The lead II electrocardiogram was recorded directly onto a Grass polygraph or was recorded at preset intervals by a programmable cardiocassette recorder.
On completion of the experiment at 24 hours of electrical stimulation or on the development of ischemic ventricular fibrillation, the heart was excised, and thrombus mass within the left circumflex coronary artery was determined after removal by careful dissection. The heart was cut into I cm thick transverse sections that were incubated in 0.5% triphenyltetrazolium chloride in 0.01 M phosphate buffer (pH 7.4). Infarct size was quantitated gravimetrically with the aid of the differential histochemical staining technique and expressed as percent of total left ventricular mass.
Experimental protocol. Three groups of conscious postmyocardial infarction dogs (n = 24) were entered into the present study. The 17 dogs in groups I and II responded to baseline pretreatment programmed ventricular stimulation with nonsustained or sustained ventricular tachycardia, and were randomized to treatment with saline vehicle (group I, n = 8) or flecainide acetate (group II, n = 9). These 17 dogs were used to evaluate the efficacy of flecainide versus vehicle to suppress the induction of ventricular tachycardia by programmed stimulation and to prevent the development of ventricular fibrillation in response to ischemia at a site remote from the previous infarction. Flecainide was administered as an intravenous loadingdose of 2.0 mg/kg body weight over 20 minutes. Saline vehicle was administered in matching volume. Posttreatment electrophysiologic monitoring and repeat programmed ventricular stimulation were performed 20 minutes after the cessation of the saline and f1ecainide loading doses in groups I and Il, respectively. Maintenance infusions of flecainide, 1.0 mg/kg per h for 4 hours in group II. or saline solution in matching volume for group I. were initiated immediately after posttreatment programmed stimulation and coincident with the initiation of intracoronary electrical stimulation for the suddendeath protocol. One flecainide-treated dog in group (( was found at postmortem examinationto have an improperly placed intracoronary stimulating electrode. resulting in a total of eight animals in both group I and group (( for the ischemic ventricular fibrillation study.
Seven additional postinfarction dogs with no inducible tachycardia on programmed ventricular stimulation (group ((I) also wereentered into this study. Previous investigations in this laboratory have shown that such dogs have an inherent low risk for the subsequent development of ischemic ventricular fibrillation ( 14) . The seven group 1Il dogs were used to evaluate the potential for f1 ecainide to exacerbate the responses to programmed ventricular stimulation or acute posterolateral ischemia. All seven dogs were given flecainide in the loading and maintenance regimens described for dogs in group II.
Drug administration. Flecainide acetate (Riker Laboratories) was administered as a loading dose of 2.0 mg/kg in 20 ml of saline (0.9% wt/vol) vehicle. administered over 20 minutes. Maintenance infusions of f1ecainide. 1.0 mg/kg per h for 4 hours, were administered in a total volume of 40 ml saline solution. A preliminary study in this laboratory (17) has demonstrated that the administration of f1ecainide in this regimen. as well as in a lower dose regimen with a loading infusion of 1.0 mg/kg, rapidly achieves and maintains plasma f1ecainide concentrations of 800 to 1.200 ng/rnl throughout the maintenance infusion.
Statistical analysis. For all evaluations, data are expressed as mean ± SEM. Pre-and posttreatment values within a given treatment group were compared by a paired Student's t test. Differences among treatment groups were analyzed by unpaired Student's t test. For all comparisons. a probability value of less than 0.05 was considered the criterion for significance .
Results
Electrophysiologic responses ( Table 1) . The electrocardiographic and electrophysiologic responses of postinfarction dogs with inducible ventricular tachycardia to vehicle (group I. n = 8) and f1ecainide (group II, n = 9) administration are summarized in Table I . Flecainide administration did not alter sinus heart rate, electrocardiographic QRS, QTc and QT intervals or the ventricular refractory period. It prolonged the PR interval, increased the ventricular excitation threshold and reduced the mean arterial pressure. Vehicle administration did not alter heart rate, blood pressure or electrocardiographic and electrophysiologic variables. In the seven postinfarctiondogs without inducible ventricular tachycardia (group Ill), f1ecainide administration slightly increased the ventricular refractory period and QTc and QT intervals, while reducing the mean arterial pressure. 
MIN
Programmed electrical stimulation (Fig. 2, Table 2 ).
The responses of postinfarction dogs with inducible ventricular tachycardia to programmed ventricular stimulation, before and after treatment with saline vehicle (group I) and f1ecainide (group II), are summarized in Figure 2 and Table  2 . The size of the underlying anterior myocardial infarction did not differ between the two groups. The administration of the loading dose of f1ecainide failed to prevent the induction of ventricular tachyarrhythmia by programmed stimulation in eight of the nine dogs tested (Fig. 3) . After flecainide, one group II dog with nonsustained tachycardia during baseline had no inducible testing tachycardia, and a second dog with sustained tachycardia during baseline testing responded to posttreatment testing with only nonsustained tachycardia. Although the cycle length of induced ventricular tachycardia tended to lengthen in some animals after f1ecainide treatment, this trend did not achieve statistical significance, and only one f1ecainide-treated dog had a prolongation of ventricular tachycardia cycle length of more than 20%. In the vehicle control group, seven of eight dogs tested responded with inducible ventricular tachycardia after saline administration, with one animal responding to pretreatment testing with a short nonsustained ventricular tachycardia that was nonresponsive after treatment. Group III animals, by definition, had no induction of ventricular tachycardia during baseline programmed stimulation testing. After f1ecainide administration, six of the seven group III dogs continued to have no inducible arrhythmia, whereas one exhibited a reproducible nonsustained tachyarrhythmia. This latter animal had a relatively large (25% of total left ventricle) anterior myocardial infarction for this group. Conscious canine model of sudden death (Table 3 , Fig. 4 ). Immediately after posttreatment programmed stimulation, an anodal current of ISO JLA was applied to the intimal surface of the left circumflex coronary artery in all 24 postinfarction dogs. The responses of the vehicle (group 1)-and f1ecainide group II-treated dogs to left circumflex coronary stimulation are summarized in Table 3 and Figure  4 . The anterior myocardial infarct size did not differ significantly between these two groups.
All eight of the vehicle-treated group I dogs (inducible ventricular tachycardia at baseline) died suddenly of ventricular fi brillation that developed in response to ischemia at a site remote from the infarct site. This fi nding is consistent with the previously reported high incidence of ischemic ventricular fibrillation in unprotected postinfarction dogs (13, 14) . The mean time to ischemic arrhythmic death in the vehicle group was 359 ± 70 minutes. In group II (f1 ecainide, inducible ventricular tachycardia at baseline) seven of the eight postinfarction dogs developed ventricular fibrill ation during acute posterolateral ischemia, with a mean time to ischemic ventricular fi brillation of 203 ± 88 minutes (Fig. 4, Table 3 ). Five of these group II dogs developed ventricular fibrill ation during the maintenance infusion. and two deaths occurred after the cessation of f1ecainide infusion. Figure 3 (lower panels) illustrates the development of ischemic ventricular fibrillat ion in a flecainide-treated postinfarction dog.
Seven flecainide-treated group III animals (no inducible ventricular tachycardia at baseline testing) also were subjected to ischemia at a site remote from the previous infarct site. The underlying anterior myocardial infarct size in the group III dogs was signifi cantly smaller than that found in have shown that flecainide is effective in terminating paroxysmal supraventricular tachycardia operating through either dual atrioventricular nodal or extranodal accessory pathways (18) (19) (20) , in suppressing chronic stable ventricular ectopic beats (7 ,8) and, in preliminary reports (9, 10) , in preventing the induction of ventricular tachycardia by programmed stimulation in some patient groups. However, patients with recent myocardial infarction and compromised left ventricular function were not included in the previous studies. The antiarrhythmic efficacy of fl ecainide in this high risk group of patients with recent myocardial injury therefore remains uncertain (2 1).
Experimental antiarrhythmic efficacy of ftecainide. The conscious canine model of sudden death described in this report has been shown to be a reliable preparation for studying sudden death in the early postmyocardial infarction period. with the animals responding to ischemia at a site remote from a previous myocardial infarction with sudden ventricular fibrillation (13-1 6). Animals with provokable ventricular tachycardia by programmed ventricular stimulation before the ischemic event generally possess a sizable myocardial infarct, constituting 18 to 25% of the left ventricular mass, and respond to a subsequent ischemic insult with a high incidence of ventricular fibrillation (13, 14) . However, postinfarction animals without provokable ventricular tachycardia at baseline testing tend to have smaller areas of myocardial infarction constituting approximately 5 to 10% of the left ventricle, and are at very low risk for ventricular fibrillation or death in response to acute ischemia ( 14) .
In a preliminary study in this laboratory, DiCarlo et al. (17) reported that the administration of flecainide acetate to anesthetized, open chest postinfarction dogs, in intravenous loading and maintenance regimens identical to those used in this study, achieved plasma drug concentrations similar to those reported in previous clinical antiarrhythmic evaluations. DiCarlo et al. (17) reported that flecainide administration failed to alter ventricular fibrillation threshold values determined in normal, border zone and infarcted myocardium, and failed to alter susceptibility to ventricular tachycardia initiation by programmed stimulation in the anesthetized dog. In the present investigation, flecainide acetate displayed minimal efficacy in suppressing ventricular tachycardia initiation by programmed pacing techniques in the conscious dog, although there was a slight but insignificant tendency toward a slowing of the rate of induced tachycardia. Furthermore, flecainide acetate was ineffective in preventing the development of ventricular fibrillation in response to an ischemic episode superimposed on the previous myocardial infarction. In this regard, flecainide acetate was far less efficacious in preventing ischemic ventricular fibrillation than were the beta-adrenergic antagonist nadolol (22), the beta-adrenergic antagonist/class III agent d.l-sotalol (23) and the class III agents amiodarone (24) , bretylium (25) and d-sotalol (16) in this preparation. The mean time to the occurrence of ischemic ventricular fibrillation was apparently shorter in the flecainide-treated dogs compared with the control dogs, but this variable is multifactorial and does not necessarily reflect a proischemic or profibrillatory tendency.
Previous studies by Wilber et al, (14) have demonstrated that postinfarction dogs with no provokable ventricular tachycardia at baseline programmed stimulation had a 90% 24 hour survival after the imposition of posterolateral ischemia. reflecting a very low vulnerability to ischemic ventricular fibrillation. In our present study, three of seven dogs (group III) without inducible ventricular tachycardia at baseline testing died suddenly in response to acute posterolateral ischemia after flecainide acetate treatment. Although the small sample size of this group prohibits any definitive conclusion regarding a proarrhythmic potential, this finding is consistent with the findings of previous studies (17, 26) which reported proarrhythmic and profibrillatory actions with fiecainide in dogs with recent myocardial infarction. It is important to note, however, that the purported proarrhythmic actions of this agent in the postinfarction dog models may be occurring at plasma concentrations in excess of those required to control arrhythmias. particularly spontaneous ectopic activity, in many patients. The potential proarrhythmic actions of flecainide additionally may be most prevalent in the setting of recent, large myocardial infarction (26) .
Conclusions. During the early postinfarction period, intravenous flecainide acetate failed to prevent the provocation of ventricular tachycardia by programmed ventricular stimulation in the majority of postinfarction dogs tested. The induced tachycardia cycle tended to lengthen after flecainide, but the trend was not significant. Flecainide also was ineffective in preventing the development of ventricular fibrillation in response to an acute ischemic event in the postinfarction dogs. In a subgroup of animals that were expected to be at a very low risk for ischemic ventricular fibrillation, arrhythmic fatality occurred in three of seven dogs subjected to posterolateral ischemia. Extrapolations regarding drug efficacy from the preclinical animal evaluation to the human situation always must be made with caution. Based strictly on the experimental features of the present animal model, our findings suggest that, during the early recovery phase of acute myocardial infarction, flecainide may not provide actions beneficial in the suppression of ventricular tachycardia and ischemia-related ventricular fibrillation. The potential for proarrhythmic effects with flecain ide in the setting of recent myocardial infarction deserves clinical awareness and further investigation.
